Call us free on 0800 862 0373

Sign in to view your quotes
Email address:
Password or PIN:

Forgotten your password? Reset it here.

European approval recommended for new skin cancer drug Zelboraf after doubling survival time

Published on 23/02/2012

A new treatment for skin cancer that almost doubles survival time will soon be available for patients with private medical insurance.

New skin cancer treatment could almost double survival time

Zelboraf (Vemurafenib) has been recommended for approval in Europe, after an international study showed that malignant melanoma patients treated with the drug gained several extra months of life.

Malignant melanoma is a type of aggressive and dangerous skin cancer, believed to be caused by over-exposure to the sun or sunbeds. Every year around 2,000 people in the UK who are diagnosed with malignant melanoma do not survive.

The study, published in the New England Journal of Medicine, looked at 132 patients in the US and Australia who were given the drug Zelboraf.

The risk of mortality was lowered by 63% in patients who received Zelboraf. It greatly improved life expectancy with an overall survival rate of 13.2 months. Chemotherapy treatment usually gives patients a 9.6 month window of life expectancy after treatment.

Zelboraf targets tumours that express a certain gene mutation, which account for about half of patients with malignant melanoma.

Zelboraf became the first and only FDA approved medicine for improving survival rates among people with this particular mutation in 2011. Other countries which have recently approved the use of the drug include Israel, Brazil, Switzerand and New Zealand.

Now, according to the European Medicines Agency, the drug has been recommended for approval in Europe, pending final authorisation by the European Commission.

Cancer Research UK said once the drug was awarded a European license it would be available to patients by applying through the Cancer Drugs Fund or through private medical cover, before being assessed by NICE for use on the NHS.

Kate Law, director of clinical and population research at Cancer Research UK, said: "it will be interesting to see what price the manufacturer charges so as not to place too great a strain on already scarce NHS resources."

To make sure you are able to access Zelboraf and other cancer drugs compare health insurance online now- private medical insurance will cover you for licensed drugs even if they aren’t available on the NHS.

© ActiveQuote Ltd. 2012

Categories:  Medical
European approval recommended for new skin cancer drug Zelboraf after doubling survival timeA new treatment for skin cancer that almost doubles survival time will soon be available for patients with private medical insurance .     tweet it on twittershare with your friends on Facebookshare with your friends on MySpaceBlog it on your LinkedIn profile

No.1 health insurance broker as rated by customers

A great service from the initial call, to finalising the agreement. I would highly recommend to my family and friends.

Review centre member

Proactive, efficient, and offered me insurance I need. I would say half price I would end up paying if I did it by myself. Many thanks.

Review centre member

Excellent service. Explained everything in detail and really helped to find the right insurance best suited to my needs - which wasn't necessarily the most expensive. 

Review centre member

Good value and the advisor was very helpful and recommended the best policy for my grandson. I would definitely use this service again and recommend to others.

Review centre member

We were contacted in good time to make a knowledgable choice. We were given plenty of options with lots of information to enable us to make the right choice.

Review centre member

The service I received was excellent, the staff member was very efficient and knowledgable. She went out of her way to get the best policy for me.

Review centre member

Great service. I really appreciated the help provided by Active Quote to arrange health insurance. The agent was very informative and proactive. Many thanks!

Review centre member

I received excellent care and attention from the first phone call till the last. Friendly, efficient and patient.

Review centre member

Staff are very helpful, friendly and polite. They call back when they say they will and keep you up to date with progress. Pleasure to deal with.

Review centre member

Very polite and friendly, and gave detailed explanations of all aspects of the cover. Reassuring to know that if you do have a problem there is someone you can contact.

Review centre member
This site is operated by Insurance Broker ActiveQuote Ltd registered in England & Wales company number 6765845.
Authorised and Regulated by the Financial Conduct Authority (FCA). Firm reference number 501109 as detailed on the Financial Services Register. Please read our Key Facts document.
For information about your rights as a consumer visit Citizens Advice.

Our insurance comparison service is free and easy for you to use, but you are responsible for making sure all your information is entered correctly, and for choosing your insurer.

This site uses cookies in order to work correctly - these are not harmful and do not contain personal information. By using this site you consent to this. I understand  Tell me more

please wait ...